Abstract: The present invention includes methods and compositions for the treatment and prevention of protozoal parasitic infections utilizing Diindolylmethane-related indoles. Additive and synergistic interaction of Diindolylmethane-related indoles with other known anti-parasitic and pro-apoptotic agents is believed to permit more effective therapy and prevention of protozoal parasitic infections. The methods and compositions described provide new treatment of protozoal parasitic diseases of mammals and birds including malaria, leishmaniasis, trypanosomiasis, trichomoniasis, neosporosis and coccidiosis.
Abstract: A compound having the following general formula (I): wherein: X is a nitrogen atom and Y is a carbon atom; or X is a carbon atom and Y is a nitrogen atom; the Ar group is an aryl or heteroaryl group; and the RN and RN? groups, together with the carbon atoms to which they are bound, form a monocyclic or bicyclic azacycloalkane group. The pharmaceutically acceptable salts thereof, the hydrates or polymorphic crystalline structures thereof, and to the racemates, diastereoisomers, or enantiomers thereof are also described.
Type:
Application
Filed:
April 20, 2012
Publication date:
January 30, 2014
Applicant:
Centre National de la Recherche Scientifique (C.N.R.S.)
Abstract: The present invention relates to non-psychoactive derivatives of tetrahydrocannabinol, which are useful in treating interstitial cystitis and relieving symptoms thereof. The invention uses (6aR,10aR)-?8-tetrahydrocannabinol-11-oic acids (hereinafter referred to as (6aR,10aR)-?8-THC-11-oic acid), as well as pharmaceutical compositions containing the (6aR,10aR)-?8-THC-11-oic acids, for treatment of interstitial cystitis in a mammal. The invention further covers methods of formulating and administering the compounds and pharmaceutical compositions as therapeutic agents in the treatment of interstitial cystitis, with particularly preferred administration routes being oral and via intravesicular instillation.
Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions, and methods for treating schizophrenia.
Type:
Application
Filed:
January 17, 2012
Publication date:
January 23, 2014
Applicant:
TARGACEPT, INC.
Inventors:
Merouane Bencherif, Geoffrey C. Dunbar, David A. Hosford, Gregory J. Gatto, Terry Hauser, Kristen G. Jordan, Anthony Carl Segreti
Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.
Type:
Application
Filed:
July 22, 2013
Publication date:
January 23, 2014
Applicant:
Targacept,Inc.
Inventors:
Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Federov, Gregory J. Gatto, Kristen G. Jordan, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Phillips
Abstract: The present invention relates to the field of weight management and the prevention and/or treatment of metabolic disorders. In particular, the present invention provides a composition comprising at least one Trpm5 inhibitor which is effective in the treatment of prevention of metabolic disorders or risk factors thereof, such as overweightness or obesity, without having to reduce food intake below metabolic needs.
Type:
Application
Filed:
March 29, 2012
Publication date:
January 23, 2014
Applicant:
NESTEC S.A.
Inventors:
Sami Damak, Philippe Cettour-Rose, Johannes Le Coutre
Abstract: The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof.
Type:
Grant
Filed:
June 22, 2011
Date of Patent:
January 14, 2014
Assignee:
Chiesi Farmaceutici S.p.A.
Inventors:
Gabriele Amari, Mauro Riccaboni, Antonio Caligiuri
Abstract: Disclosed herein are methods of treating a patient suffering from a cognitive disorder using compounds of Formulas (1) and (2) wherein the variables have the meaning disclosed in the specification.
Type:
Grant
Filed:
March 4, 2008
Date of Patent:
January 7, 2014
Assignee:
Allergan, Inc.
Inventors:
John E. Donello, Fabien J. Schweighoffer, Lauren M. Luhrs
Abstract: Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders.
Type:
Application
Filed:
August 26, 2013
Publication date:
January 2, 2014
Applicant:
AXIKIN PHARMACEUTICALS, INC.
Inventors:
Yingfu Li, Kevin Bacon, Hiromi Sugimoto, Keiko Fukushima, Kentaro Hashimoto, Makiko Marumo, Toshiya Moriwaki, Noriko Nunami, Naoki Tsuno, Klaus Urbahns, Nagahiro Yoshida
Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Application
Filed:
August 16, 2013
Publication date:
December 19, 2013
Applicant:
BAYER HEALTHCARE AG
Inventors:
Joachim Luithle, Frank-Gerhard Bob, Christina Erb, Katrin Schnizler, Timo Flessner, Marja Van Kampen, Christoph Methfessel
Abstract: The present invention relates to the discovery that, in human cancer, an 11q deletion of ATM together with an increase in ATR and CHEK1 expression correlates with resistance to ionizing radiation which could be overcome by inhibition of the ATR/CHEK1 pathway. It provides for methods of identifying patients unlikely to exhibit an adequate response to radiation therapy and/or chemotherapy who may benefit from ATR/CHEK1 pathway inhibition, as well as methods of treating said patients.
Type:
Application
Filed:
June 10, 2013
Publication date:
December 19, 2013
Applicant:
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
Inventors:
Susanne M. Gollin, Rahul Atul Parikh, Xin Huang
Abstract: A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.
Type:
Application
Filed:
January 30, 2012
Publication date:
November 28, 2013
Applicant:
SK BIOPHARMACEUTICALS CO., LTD.
Inventors:
Cheol Young Maeng, Young Koo Jang, Su Bong Cha, Hye Won Shin, Chan Mi Joung, Hwa Ryun Cha, Eun Jung Yi
Abstract: This application is directed to a-neuronal nicotinic receptor agonists selective for ?7-subtype that are useful for improving cognition impairment in patients having schizophrenia, a schizophreniform disorder or a related schizophrenia spectrum psychotic disorder. Compounds and compositions containing such compounds, and methods of using such compound and compositions are described herein.
Type:
Application
Filed:
March 14, 2013
Publication date:
November 28, 2013
Applicant:
AbbVie Inc.
Inventors:
George M. Haig, Jeffrey F. Waring, Chih-Hung Lee, Deli Wang
Abstract: Provided herein are azolyl urea compounds for treatment of CSF-1R kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.
Abstract: Provided is a pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo-[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X? with a single negative charge is associated with the positive charge of the nitrogen atom; and (ii) a phosphodiesterase IV inhibitor and methods of using the same.
Type:
Application
Filed:
July 11, 2013
Publication date:
November 21, 2013
Inventors:
Maria Dolors FERNANDEZ FORNER, Maria PRAT QUINONES, Maria Antonia BUIL ALBERO
Abstract: Combinations comprising (a) a ?2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.
Type:
Application
Filed:
July 25, 2013
Publication date:
November 21, 2013
Inventors:
Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
Abstract: The present invention relates to heterocyclic compounds of formula (I) having affinity to muscarinic receptors, a pharmaceutical composition containing the compounds, as well as the use of the compounds for the preparation of a medicament for treating, alleviating or preventing muscarinic receptor mediated diseases and conditions.
Type:
Grant
Filed:
November 21, 2011
Date of Patent:
November 19, 2013
Assignee:
AbbVie B.V.
Inventors:
Axel Stoit, Hein K. A. C. Coolen, Cornelis G. Kruse, Louise Terwel
Abstract: The present invention features inhibitors of nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing conditions such as, for example, stroke, reperfusion injury, neurodegeneration, head trauma, CABG, migraine headache with and without aura, migraine with allodynia, central post-stroke pain (CPSP), neuropathic pain, morphine/opioid induced tolerance and hyperalgesia.
Type:
Grant
Filed:
May 6, 2011
Date of Patent:
November 19, 2013
Assignee:
NeurAxon, Inc.
Inventors:
Shawn Maddaford, Jailall Ramnauth, Suman Rakhit, Joanne Patman, Paul Renton, Subhash C. Annedi
Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.
Abstract: A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof.
Type:
Application
Filed:
January 30, 2012
Publication date:
November 7, 2013
Inventors:
Cheol Young Maeng, Young Koo Jang, Su Bong Cha, Hye Won Shin, Chan Mi Joung, Eun Jung Yi
Abstract: The present invention provides methods and compositions for modulating certain metabolic processes and for treating a variety of disorders associated with metabolic syndrome, including insulin related disorders, ischemia, oxidative stress, atherosclerosis, hypertension, obesity, abnormal lipid metabolism, and stroke by administering an effective dose of a chloroquine compound. The invention also provides methods and compositions relating to administering an effective dose of a chloroquine compound in combination with at least a second pharmaceutically active ingredient or compound including an antihyperglycemic diabetes treatment, an antihypertensive agent, an antithrombotic agent, and/or an inhibitor of cholesterol synthesis or absorption.
Type:
Application
Filed:
March 14, 2013
Publication date:
November 7, 2013
Inventors:
Michael B. Kastan, Clay F. Semenkovich, Jochen Schneider
Abstract: The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Type:
Application
Filed:
September 21, 2012
Publication date:
October 24, 2013
Inventors:
Simon Everitt, Ronald Knegtel, Michael Mortimore, Alistair Rutherford
Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.
Type:
Application
Filed:
October 18, 2011
Publication date:
October 24, 2013
Applicant:
ELCELYX THERAPEUTICS, INC.
Inventors:
Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
Abstract: The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for the preparation of such a compound, compositions which contain such a compound, and therapeutic uses of such a compound.
Abstract: The combined use of (R)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3R)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) with a substantial storage component is provided.
Type:
Application
Filed:
June 4, 2013
Publication date:
October 10, 2013
Inventors:
Karin Juliette Van Charldorp, Brigitte Johanna Fanny Bosman, Monique Maria Alida Klaver, Alberto Garcia Hernandez, Tennis Edwin Drogendijk
Abstract: Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids.
Abstract: The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
Type:
Application
Filed:
September 21, 2012
Publication date:
October 3, 2013
Inventors:
Simon Everitt, Ronald Knegtel, Michael Mortimore, Alistair Rutherford
Abstract: Combinations comprising (a) a PDE4 Inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.
Type:
Application
Filed:
May 21, 2013
Publication date:
September 26, 2013
Inventors:
Jordi Gras Escardo, Jesus Llenas Calvo, Hamish Ryder, Pio Orviz Diaz
Abstract: The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems.
Type:
Grant
Filed:
May 26, 2011
Date of Patent:
September 24, 2013
Assignee:
Targacept, Inc.
Inventors:
Merouane Bencherif, Lisa Benson, Gary Maurice Dull, Nikolai Fedorov, Gregory J. Gatto, Kristen G. Jordan, Anatoly A. Mazurov, Lan Miao, Julio A. Munoz, Inigo Pfeiffer, Sondra Pfeiffer, Teresa Phillips
Abstract: The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes, methods of preparing the compounds and methods of treatment using the compounds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroaromatic, preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compounds exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the ?7 nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission.
Abstract: A method for treating inflammation comprising administering to a patient (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof or (R)-7-(2-methoxyphenyl)-N-(quinuclidin-3-yl)benzofuran-2-carboxamide or certain other alpha 7 receptor agonists combination with an acetylcholinesterase inhibitor.
Abstract: The subject invention provides stereoisomeric compounds of formula (X): wherein the variables are as defined herein, and compositions for the safe and effective treatment of various gastrointestinal disorders including, but not limited to, gastroparesis, gastroesophageal reflux and related conditions. The compounds of the subject invention are also useful in treating a variety of conditions involving the central nervous system.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
September 3, 2013
Assignee:
Armetheon, Inc.
Inventors:
Ian Irwin, Monica Palme, Cyrus Becker, Pascal J. Druzgala
Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in a delayed-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of an pharmaceutical composition comprising an analgesic agent.
Abstract: A method for improving cognition comprising administering to a patient certain alpha-7 receptor agonists and an acetylcholinesterase inhibitor is described together with related compositions.
Abstract: The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory.
Type:
Grant
Filed:
June 29, 2009
Date of Patent:
August 27, 2013
Assignee:
Bayer Healthcare AG
Inventors:
Joachim Luithle, Frank-Gerhard Böb, Christina Erb, Katrin Schnitzler, Timo Flessner, Marja Van Kampen, Christoph Methfessel
Abstract: Methods and compositions for reducing the frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising an analgesic agent formulated in an extended-release formulation. Another method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising multiple active ingredients formulated for extended-release. Yet another method comprises administering to a subject in need thereof an effective amount of a diuretic followed with another administration of a pharmaceutical composition comprising an analgesic agent formulated for extended-release.
Abstract: The present invention relates to a method of treating attention deficit hyperactivity disorder in a subject. This method includes selecting a subject with attention deficit hyperactivity disorder and administering to the selected subject a sodium/hydrogen exchanger inhibitor under conditions effective to treat the subject for attention deficit hyperactivity disorder. Methods of identifying compounds suitable to treat attention deficit hyperactivity disorder are also disclosed.
Type:
Application
Filed:
February 15, 2013
Publication date:
August 22, 2013
Applicant:
The Research Foundation of State University of New York
Inventor:
The Research Foundation of State University of New York
Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the ?7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Abstract: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide in combination with a steroid, and methods of using it for treatment of respiratory disorders.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
August 20, 2013
Assignee:
Almirall, S.A.
Inventors:
Maria Dolors Fernandez Forner, Maria Prat Quinones, Maria Antonia Buil Albero
Abstract: The invention relates to use of compositions in therapeutics containing a compound having general formula (I): Wherein R, R1, R2, X and n are as described herein.
Type:
Grant
Filed:
October 5, 2009
Date of Patent:
August 20, 2013
Assignee:
SANOFI
Inventors:
Gihad Dargazanli, Genevieve Estenne-Bouhtou, Pascale Magat, Benoit Marabout, Pierre Roger
Abstract: The invention concerns fumarate salts of solifenacin, as well as pharmaceutical compositions comprising fumarate salts of solifenacin. The invention furthermore concerns a process for preparing solifenacin and salts thereof. The fumarate salt provides improved properties over the known solifenacin salts, especially in terms of its stability. The novel process for its preparation is furthermore improved over known processes for preparing solifenacin in that it provides a higher yield and recovers a greater amount of starting material.
Type:
Application
Filed:
July 5, 2011
Publication date:
August 8, 2013
Applicant:
CRYSTAL PHARMA, S.A.U.
Inventors:
Gerardo Gutiérrez Fuentes, Antonio Lorente Bonde-Larsen, Jaime del Campo López-Bachiller, Celso Sandoval Rodríguez, Yolanda Fernández Sainz
Abstract: Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.
Abstract: Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed. Agonists and antagonists of nAChR?7 and their use as therapeutic agents for treating and managing inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are disclosed.
Type:
Application
Filed:
June 24, 2011
Publication date:
August 1, 2013
Applicants:
OKLAHOMA MEDICAL RESEARCH FOUNDATION, THE JOHNS HOPKINS UNIVERSITY
Inventors:
Xuhang Li, Philip Alex, Michael B. Centola
Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
Abstract: The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo[2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders.
Type:
Grant
Filed:
November 26, 2008
Date of Patent:
July 23, 2013
Assignee:
Laboratorios Salvat, S.A.
Inventors:
Juan Lorenzo Catena Ruiz, José Hidalgo Rodriguez, María del Carmen Serra Comas, Isabel Masip Masip
Abstract: Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described.